The Pfizer and Moderna Covid vaccines should remain highly effective against two coronavirus variants first identified in India, according to new research carried out by US scientists.
May 17, 2021
0
168
The Lundquist Institute spinoff start-up company Vitalex Biosciences, founded by researcher Dr. Ashraf Ibrahim, is producing an antibody that stems the spread of mucormycosis, a deadly fungal infection with an overall mortality ...
May 17, 2021
0
3
The investigational drug evinacumab reduced triglycerides in patients with severe hypertriglyceridemia (sHTG) and a history of hospitalizations for acute pancreatitis in a phase 2 global study led by Mount Sinai. The fully ...
May 16, 2021
0
3
The most complete picture yet is shedding light on how antibodies produced in people who effectively fight off SARS-CoV-2 work to neutralize the part of the virus responsible for causing infection. In the journal Science, ...
May 4, 2021
0
267
New research from the UVA Cancer Center could rescue once-promising immunotherapies for treating solid cancer tumors, such as ovarian, colon and triple-negative breast cancer, that ultimately failed in human clinical trials.
Apr 6, 2021
0
111
A new antibody that can mount a double attack on the SARS-CoV-2 virus by binding to two different sites on the spike protein is starting human trials, leading to hopes of an antibody therapy that can maintain its effectiveness ...
Mar 25, 2021
0
5
An international consortium that includes researchers at Karolinska Institutet has developed a double antibody that targets two sites of the SARS-CoV-2 virus, thereby preventing the virus from mutating to resist the therapy. ...
Mar 25, 2021
0
292
A team of researchers has found disrupting the interaction between cancer cells and certain immune cells is more effective at killing cancer cells than current immunotherapy treatments.
Mar 19, 2021
0
129
The vast majority of people infected with SARS-CoV-2 clear the virus, but those with compromised immunity—such as individuals receiving immune-suppressive drugs for autoimmune diseases—can become chronically infected. ...
Mar 16, 2021
0
172
Evotec, a drug company headquartered in Hamburg, Germany, has begun a phase 1 clinical trial of a monoclonal antibody against the chikungunya virus that was identified at Vanderbilt University Medical Center.
Mar 5, 2021
0
2
